Novo after crucial data from competitor: Welcomes drug R&D

Investors in both Novo Nordisk and US firm Eli Lilly are highly satisfied with the results from Lilly's grand diabetes hope, tirzepatide. Novo Nordisk already has a potential new superdrug in its pipeline.
Photo: Mike Blake/REUTERS / X00030
Photo: Mike Blake/REUTERS / X00030
BY BENJAMIN WERNER CHRISTENSEN, FINANS, TRANSLATED BY NIELSINE NIELSEN

Things looked really great, but not to the extent that the firms have hit a home run.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading